Work

Real-world retrospective study on the efficacy and safety of anti-IgE therapy combined with rush immunotherapy in allergic asthma

Year: 2025

Type: article

Abstract: Background: Research on the combination of biologics with rush immunotherapy (RIT) remains scarce, particularly regarding safety and efficacy data in pediatric and hypersensitive populations undergoing rapid desensitization or concurrent biologic therapy. Furthermore, regarding RIT, it remains unclear which patients can effectively reduce the occurrence of adverse reactions when combined with biologics, and which patients fail to achieve such a reduction with this combination therapy. Methods: = 69). Stratified analyses were conducted based on age, mite sIgE levels, total IgE(T-IgE) levels, and sIgE to T-IgE ratios. Outcomes included systemic adverse reaction (SR) rates, RIT completion rates, improvements in clinical parameters following omalizumab intervention, and 1-year follow-up efficacy across subgroups. Results: < 0.05).Subgroup with sIgE/T-IgE ratios >16% achieved substantially greater improvements in ACQ scores and daily medication burden compared to those with ratios <16% during the 12-month intervention. Furthermore, this study reaffirmed the age-dependent efficacy correlation, with pediatric patients demonstrating superior therapeutic outcomes to adult patients. Conclusions: Regarding the safety of dust mite rush immunotherapy for allergic asthma, Omalizumab significantly reduces the incidence of SRs in high-risk populations (sIgE grades 3-6 and sIgE/T-IgE ≥10%), whereas it demonstrates limited efficacy in low-risk subgroups (sIgE grades 1-2 and sIgE/T-IgE <10%).

Source: Frontiers in Allergy

DOI: 10.3389/falgy.2025.1717446